Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Growth Hormone Deficiency (GHD) in 9 Major Markets
Growth Hormone Deficiency (GHD) results from the destruction of normal pituitary and hypothalamic tissue and is characterized by the inadequate secretion of growth hormone (GH), from the anterior pituitary gland. GHD can occur at any point during an individual’s life, but is primarily defined as being of Childhood onset (CO) or Adult onset (AO). The majority of CO is congenital whereas AO forms tend to be acquired or idiopathic.
This report provides the current prevalent population for GHD across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, India and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of GHD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for GHD include:
• Diabetes Mellitus & other issues with glucose regulation (including IGT and metabolic syndrome)
• Hypertension
• Obesity
• Osteopenia, osteoporosis & increased fractures
• Liver disease
• Cerebrovascular diseases
• Cardiovascular diseases
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global GHD’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of GHD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on GHD’s prevalent population.
• Identify sub-populations within GHD which require treatment.
• Gain an understanding of the specific markets that have the largest number of GHD patients.
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Growth Hormone Deficiency
o GHD by Onset Type
o Aetiology of GHD
o Features of Pituitary Adenomas
o Co-morbidities of GHD
o Concomitant Pituitary Deficiencies of GHD
o Bone Status of GHD Patients
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Prevalence of GHD, total (000s)
• Prevalence of GHD, males (000s)
• Prevalence of GHD, females (000s)
• GHD patients by onset type, total (000s)
• GHD patients by aetiology, total (000s)
• Acquired GHD patients by main cause, total (000s)
• Functional status of Pituitary adenomas in patients with Acquired GHD, total (000s)
• Size of Pituitary adenomas in patients with Acquired GHD, total (000s)
• GHD patients with Dyslipidaemia, total (000s)
• GHD patients with T2DM, total (000s)
• GHD patients with Metabolic Syndrome, total (000s)
• GHD patients with Hypertension, total (000s)
• GHD patients with Arthritis, total (000s)
• GHD patients with Visual Field Loss, total (000s)
• GHD patients with TSH Deficiency, total (000s)
• GHD patients with ACTH Deficiency, total (000s)
• GHD patients with LH/FSH Deficiency, total (000s)
• GHD patients with ADH Deficiency, total (000s)
• GHD patients with isolated GH Deficiency, total (000s)
• GHD patients by bone density, total (000s)
• GHD patients with bone fractures, total (000s)
• GHD patients with vertebral fractures, total (000s)
• GHD patients with non-vertebral fractures, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of GHD by 5-yr age cohort, males (000s)
• USA Prevalence of GHD by 5-yr age cohort, females (000s)
• France Prevalence of GHD by 5-yr age cohort, males (000s)
• France Prevalence of GHD by 5-yr age cohort, females (000s)
• Germany Prevalence of GHD by 5-yr age cohort, males (000s)
• Germany Prevalence of GHD by 5-yr age cohort, females (000s)
• Italy Prevalence of GHD by 5-yr age cohort, males (000s)
• Italy Prevalence of GHD by 5-yr age cohort, females (000s)
• Spain Prevalence of GHD by 5-yr age cohort, males (000s)
• Spain Prevalence of GHD by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of GHD by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of GHD by 5-yr age cohort, females (000s)
• Brazil Prevalence of GHD by 5-yr age cohort, males (000s)
• Brazil Prevalence of GHD by 5-yr age cohort, females (000s)
• Japan Prevalence of GHD by 5-yr age cohort, males (000s)
• Japan Prevalence of GHD by 5-yr age cohort, females (000s)
• India Prevalence of GHD by 5-yr age cohort, males (000s)
• India Prevalence of GHD by 5-yr age cohort, females (000s)
